top of page

logoPioneer plein.png

Posters et publications

Découvrez les posters et publications du projet PIONeeR

ESMO 2024: PK/PD analysis of pembrolizumab, nivolumab and atezolizumab in NSCLC patients: the PIONeeR trial

SITC23

SITC 2023: Regulatory T-cell tumor infiltration improves advanced NSCLC patients’ outcome under ≥ 2nd line anti-PD1/L1monotherapy in The PIONeeR Project

ESMO IO 22

ESMO IO 2022: Comprehensive biomarkers analysis to predict efficacy of PD1/L1 immune checkpoint inhibitors in combination with chemotherapy: a subgroup analysis of the Precision Immuno-Oncology for advanced Non-Small CEll Lung CancER (PIONeeR) trial

SITC22 Brightplex

SITC 2022: Brightplex® TCE and Brightplex® MDSC assays combination improve advanced NSCLC patient stratification under anti-PD1/L1 immunotherapy in the PIONeeR project

SITC22 new target

SITC 2022: Anti-HVEM mAB therapy improves antitumoral immunity both in vitro and in a novel mice model expressing human HVEM and BTLA molecules using HVEM expressing tumors

SITC 22 new targets

AACR 2022: Comprehensive biomarkers analysis to explain resistances to PD1/L1 ICIs: The Precision Immuno-Oncology for advanced Non-Small CEll Lung CancER (PIONeeR) trial

SITC 21

SITC 2021: Preliminary PIONeeR Biomarker data analysis

ESMO 20

ESMO 2020: PIONeeR presentation

Webinar

Evaluating Biomarkers During Clinical Trials for Immunotherapies: A Case Study on the PIONeeR Project (Webinar by HalioDx, 2019)

WCLC 19

WCLC 2019 : PIONeeR study precision immuno-oncology for advanced nonsmall cell lung cancer patients with PD1/L1 ICI resistance

SITC 19

SITC 2019: Immunogram to decipher PD1/L1 ICI resistance: a proof of concept in advanced NSCLC patients of the PIONeeR Project

bottom of page